Artia Global Partners’s Soleno Therapeutics SLNO Stock Holding History

Artia Global Partners’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-68,490	Closed	-$2.29M	–	56
2026 Q1	$2.29M	Sell	68,490 -465,208	-87%	-$18.2M	0.46%	35
2025 Q4	$24.7M	Sell	533,698 -138,478	-21%	-$7.59M	3.5%	8
2025 Q3	$45.4M	Buy	672,176 +177,752	+36%	+$13.2M	7.2%	4
2025 Q2	$41.4M	Sell	494,424 -4,049	-0.8%	-$303K	9.97%	4
2025 Q1	$35.6M	Buy	498,473 +4,049	+0.8%	+$197K	9.01%	3
2024 Q4	$22.2M	Buy	494,424 +220,000	+80%	+$11.4M	7.94%	1
2024 Q3	$13.9M	Buy	274,424 +180,000	+191%	+$8.62M	3.78%	6
2024 Q2	$3.85M	Buy	94,424 +53,500	+131%	+$2.27M	0.74%	19
2024 Q1	$1.75M	Buy	+40,924	New	+$1.85M	0.35%	30

Artia Global Partners's SLNO Position: Q2 2026 in Review

Artia Global Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 68,490 shares — an estimated $2.29M sold.

Artia Global Partners first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $45.4M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Artia Global Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Artia Global Partners sold 68,490 Soleno Therapeutics shares in Q2 2026, an estimated $2.29M.
Artia Global Partners first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
Artia Global Partners's Soleno Therapeutics position peaked at $45.4M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.